Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion

References

• Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiol Rev 2001; 81:1535-65; PMID:11581496.
   PubMed Web of Science ®Google Scholar
• MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Reviews 1998; 50:151-96; PMID:9647865.
   PubMed Web of Science ®Google Scholar
• Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002; 16:116-27; PMID:11773443.
   PubMed Web of Science ®Google Scholar
• Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407:538-41; PMID:11029009.; http://dx.doi.org/10.1038/35035131
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492-502; PMID:16757721.; http://dx.doi.org/10.1001/jama.295.21.2492
   PubMed Web of Science ®Google Scholar
• Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006; 8:R34; PMID:16846532.
   PubMed Web of Science ®Google Scholar
• Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol 1998; 12:842-54; PMID:9626660.; http://dx.doi.org/10.1210/mend.12.6.0121
   PubMed Web of Science ®Google Scholar
• Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 1992; 89:4037-41; PMID:1570330.; http://dx.doi.org/10.1073/pnas.89.9.4037
   PubMed Web of Science ®Google Scholar
• Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993;25:1-9; PMID:8518404.; http://dx.doi.org/10.1007/BF00662395
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605-13; PMID:15117982.
   PubMed Web of Science ®Google Scholar
• JavanMoghadam S, Hands AM, Keyomarsi K. Breaking the cycle: an insight into the role of ERα in eukaryotic cell cycles. J Carcinog 2011; 10:25; In Press; PMID:22190867.
   PubMedGoogle Scholar
• Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003; 10:179-86; PMID:12790780.; http://dx.doi.org/10.1677/erc.0.0100179
   PubMed Web of Science ®Google Scholar
• Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999; 53:217-27; PMID:10369068.; http://dx.doi.org/10.1023/A:1006186719322
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393-8; PMID:12917485.; http://dx.doi.org/10.1073/pnas.1732912100
   PubMed Web of Science ®Google Scholar
• Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010;4:209-29; PMID:20537966.; http://dx.doi.org/10.1016/j.molonc.2010.04.006
   PubMed Web of Science ®Google Scholar
• Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40:2667-75; PMID:15571950.; http://dx.doi.org/10.1016/j.ejca.2004.08.021
   PubMed Web of Science ®Google Scholar
• Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992;84:580-91; PMID:1556769.; http://dx.doi.org/10.1093/jnci/84.8.580
   PubMed Web of Science ®Google Scholar
• Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 2000; 14:999-1009; PMID:10894150.; http://dx.doi.org/10.1210/mend.14.7.0492
   PubMed Web of Science ®Google Scholar
• Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A 1992; 89:11538-42; PMID:1454845.; http://dx.doi.org/10.1073/pnas.89.23.11538
   PubMed Web of Science ®Google Scholar
• Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer 2004; 90:20-5; PMID:14710200.
   PubMed Web of Science ®Google Scholar
• Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004; 64:3198-208; PMID:15126360.; http://dx.doi.org/10.1158/0008-5472.CAN-03-3672
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51:3602-9; PMID:1711413.
   PubMed Web of Science ®Google Scholar
• Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 2008; 7:2434-40; PMID:18677105.; http://dx.doi.org/10.4161/cc.6364
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999; 96:7797-802; PMID:10393901.; http://dx.doi.org/10.1073/pnas.96.14.7797
   PubMed Web of Science ®Google Scholar
• Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998; 17:2393-402; PMID:9811471.; http://dx.doi.org/10.1038/sj.onc.1202322
   PubMed Web of Science ®Google Scholar
• Pedrali-Noy G, Spadari S, Miller-Faures A, Miller AO, Kruppa J, Koch G. Synchronization of HeLa cell cultures by inhibition of DNA polymerase alpha with aphidicolin. Nucleic Acids Res 1980; 8:377-87; PMID:6775308.; http://dx.doi.org/10.1093/nar/8.2.377
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Conte D, Jr., Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995; 11:941-50; PMID:7675453.
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993; 90:1112-6; PMID:8430082.; http://dx.doi.org/10.1073/pnas.90.3.1112
   PubMed Web of Science ®Google Scholar